Trump's 100% Drug Tariffs Reshape Pharma; $25.5B M&A Spree

Hundred-percent tariffs on imported brand-name drugs are now signed — and the companies exempt from paying them may tell you more than the rate itself.

Add a thirty-year pipeline growth streak snapping, twenty-five billion in M&A in eight days, and the oral obesity war officially becoming a two-horse race. Friday's got a lot to carry.

Welcome to The Pharma Closeout for Friday, April 3rd, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

The Trump administration signed it yesterday — hundred-percent tariffs on imported patented pharmaceutical products and active ingredients, executed under a Section 232 investigation. Hundred percent. On paper, that's an industry-altering number. But here's where it gets interesting. Per STAT, many large drugmakers won't actually pay that rate. They've individually negotiated pricing deals with the White House. Company by company, behind closed doors.

Which reframes the entire policy. This isn't a tariff in the traditional sense — it's a pricing negotiation lever with a very visible threat attached. The companies that cut deals walk away with exemptions. The ones that didn't are staring at a cost structure that breaks their import economics overnight.

And the scope keeps widening. STAT reported separately that smaller drugmakers are now at the table too, negotiating their own agreements to avoid the hit. So the White House has built a bilateral pricing architecture — not through legislation, not through CMS, but through trade authority. One deal at a time.

The UK arrangement is the international blueprint. Per the USTR announcement, the UK secured tariff-free access for its drugs into the U.S. market — in exchange for agreeing to pay higher prices on new American medicines coming into the UK. That kind of direct reciprocity didn't exist ninety days ago.

Fierce Pharma ran a deep dive this morning on the reshoring acceleration. Tens of billions in new U.S. manufacturing pledges. But the Reshoring Institute made a critical point in that piece: those investments don't translate into actual domestic production for years. The concrete hasn't even been poured on most of these facilities.

That's the mismatch everyone should be modeling. The tariff creates immediate pricing pressure today. The supply chain response is a multi-year buildout. Companies with existing U.S. manufacturing capacity have a structural edge right now — and that edge compounds every quarter the buildout takes.

What makes this genuinely different from a standard trade action is the opacity. We don't know which companies have secured exemptions and which haven't. STAT sourced those details from people with direct knowledge of the meetings. None of it appears in any public filing.

And for anyone doing competitive modeling, that's the real disruption. You can't accurately project a competitor's cost structure if you don't know whether they're paying a hundred-percent tariff or zero. The policy just introduced information asymmetry at exactly the level where commercial planning lives. That blind spot doesn't resolve until companies start disclosing — and they have no obligation to.

That tariff uncertainty is landing on an industry that's already reshuffling at speed. Twenty-five-and-a-half billion dollars in announced acquisitions over eight days. Let me run the board. Biogen acquiring Apellis Pharmaceuticals — five-point-six billion. Apellis stock surged a hundred and thirty-five percent in a single session to forty dollars and twenty-three cents. Lilly closed its six-point-three-billion-dollar buyout of Centessa, picking up two sleep disorder drugs to fill a gap in its neuroscience portfolio. And Merck is nearing a roughly six-billion-dollar all-cash deal for Terns Pharma to bolster oncology, per the Financial Times and Reuters.

What's worth spending a beat on is the deal architecture. Both the Biogen-Apellis and Lilly-Centessa transactions use contingent value rights — milestone-linked payments that only trigger if the acquired assets hit specific clinical or regulatory benchmarks. Two mega-deals in the same week structured around CVRs isn't coincidence. It's a valuation gap made visible.

Let's bring in Marcus Webb on what that pattern signals for the rest of the year.

Outside M&A, two capital signals worth noting. Blackstone raised six-point-three billion for its latest life sciences fund — a record haul that tells you exactly where institutional money sees durable opportunity. And BioPharma Dive reported that six biotech IPOs priced in Q1 with a median raise of two-hundred-eighty-seven-point-five million, far above the recent-year pace.

Now contrast all that deal energy with the Citeline report that dropped this morning: the global biopharma R&D pipeline has contracted for the first time in thirty years. Fewer drugs in active development than the year before. Developers trimming portfolios, starting fewer new programs. Layer that onto tariff uncertainty, a regulatory environment that's been unpredictable all quarter, and the cost pressures we just described — and the M&A surge isn't surprising. It's the logical consequence. When you can't grow the pipeline organically, you acquire it. The question is whether bought pipelines perform as well as built ones. History says: not always.

Maya, the FDA had a busy week of its own — and the Foundayo approval is the one everyone's watching.

Right. FDA approved Eli Lilly's oral orforglipron, branded Foundayo, on April 1st. That puts Lilly directly into the commercial ring against Novo Nordisk's oral Wegovy, which launched about four months earlier.

Analysts are already pricing in an aggressive launch. Novo isn't conceding anything — Endpoints reported Novo publicly claiming its obesity pill is superior. Their own qualifier, though: only a head-to-head trial can prove it. And nobody's running one yet.

Meanwhile, Novo launched a subscription pricing model for Wegovy through telehealth providers this week — twelve-month plans at two-forty-nine a month for the injection pen. So the competitive battle isn't just clinical — it's access architecture. Lilly's formulary strategy and distribution buildout for Foundayo will be what determines early share capture. The efficacy argument stays unresolved without a head-to-head. The commercial execution gap is what the market will actually price.

Sharper pain this week for ORIC Pharmaceuticals. The stock dropped between twenty-eight and thirty-six percent — depending on the measurement window — after the company selected four hundred milligrams once daily as the recommended Phase 3 dose for rinzimetostat in combination with darolutamide for mCRPC.

The irony is the data wasn't bad. Eighty-four percent five-month radiographic progression-free survival in a post-abiraterone population — in patients who've already progressed through a potent AR-pathway inhibitor, that's a signal most oncologists would want to see validated. The market punished the dose selection, not the biology. Himalayas-1 will tell us whether the four-hundred-milligram ceiling constrains efficacy at registrational scale or whether ORIC read the dose-response curve correctly.

Three more regulatory items, rapid fire. Pfizer and BioNTech paused a COVID vaccine study in healthy adults fifty to sixty-four — enrollment was too low to generate the data FDA required. That trial was tied to a post-marketing commitment Commissioner Makary imposed on all approved COVID vaccines. Separately, BioNTech is shutting its Singapore manufacturing facility. Gilead terminated the Phase 2/3 Wonders-2 trial of two long-acting HIV pills after an FDA clinical hold that's been in effect since last June. And FDA extended Orca Bio's cell therapy review by three months — new PDUFA date is July 6th, following a CMC submission the agency classified as a major amendment.

Step back from the specifics and the pattern is hard to ignore. A post-marketing study that can't enroll. A clinical hold that forced a termination. A review extension triggered by manufacturing data requests. Three different programs, three different mechanisms — but in each case, the regulatory process itself became the binding constraint, not the underlying science. That's the operating environment feeding the pipeline contraction we just talked about. Developers aren't just cutting programs because of cost. They're cutting them because the path through the agency has become harder to predict.

Looking ahead — the Foundayo launch trajectory is the single most important commercial catalyst going into Q2. How fast Lilly scales manufacturing, how payers position it relative to oral Wegovy, and whether the subscription pricing model Novo just launched creates a stickiness advantage for the incumbent. Ambrosia Biosciences also closed a hundred-million-dollar Series B this week for its own oral GLP-1 candidate — so the field is expanding even as the two leaders are still establishing position.

On the tariff front, the UK deal is the template — but the real question is which countries follow and on what timeline. Every bilateral arrangement reshapes competitive dynamics for companies still manufacturing outside the U.S. The next few weeks of negotiations may end up mattering more than the tariff rate that made the headlines.

That is your Pharma Closeout for Friday, April 3rd. Hundred-percent tariffs creating a two-tier cost landscape, twenty-five billion in deals with CVRs as the new default architecture, Foundayo officially in the market against Wegovy, ORIC taking a dose-selection hit, and a thirty-year pipeline growth streak broken. This is a week that's going to ripple for a while. If this briefing helps you stay across the space, follow us on Spotify and drop a rating — it's the fastest way more people in this industry find us.

Go enjoy the weekend. We'll be back Sunday to pull the whole week together. See you then.